Biomarkers help to detect cancer at an early stage and facilitate noninvasive diagnosis at high-speed by utilizing different proteomic and genomic markers. The increasing prevalence of cancer is a prime factor boosting the cancer biomarkers market growth. In addition to this, the market is also witnessing a significant rise on account of the growing demand for drug discovery and development for various cancer types. Additionally, many pharmaceutical companies are investing massive amounts into research and development of novel biomarkers for cancer therapeutics. Moreover, many clinical trials and pipeline studies are currently heading towards the end stages of development, and their market entry is likely to attract high cancer biomarkers market revenue in the coming years. On the flip side, the market may face challenges in terms of reimbursement policies supported by the governments.
Understanding Your Pathology Report: Benign Breast Conditions
What is a Pathology Report
Pathology reports are written in medical language because they are prepared for health care providers. This can make some of the wording hard to understand. However, understanding the basic parts of the report can help you be better informed about your diagnosis. Different pathology labs may use different terms to describe the same information. So, your report may not have the exact wording found here. Also, some tests are only done when invasive breast cancer or certain types of breast cancer are found.
What Cancer Patients Should Know About Their Pathology Reports
What might the pathology report say about the physical and chemical characteristics of the tissue? A pathology report is a document that contains the diagnosis determined by examining cells and tissues under a microscope. The report may also contain information about the size, shape, and appearance of a specimen as it looks to the naked eye. This information is known as the gross description.
Ki is a cancer antigen protein that's found in growing, dividing cells but is absent in the resting phase of cell growth when cells are not growing. However, its use in breast cancer is controversial. The Ki test may be performed on a sample of breast cancer tissue to help predict the tumor's aggressiveness. While the Ki proliferation marker test is increasingly ordered by doctors, its overall benefit, specifically when it comes to making decisions about treatment, is not certain.